・Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. ・The company added that it no longer expects to initiate the trial in question in the ...

Fintel reports that on October 6, 2025, LUCID CAPITAL MARKETS initiated coverage of Cassava Sciences (NasdaqCM:SAVA) with a Buy recommendation. As of September 30, 2025, the average one-year price ...

Cassava Sciences Inc. (NASDAQ: SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company’s trial for simufilam Following previously reported communications ...

Cassava Sciences shares fell after the company said the Food and Drug Administration had put a hold on its epilepsy drug trial. The stock fell 15% to $2.41 in after-hours trading Thursday. Through the ...

(RTTNews) - Trading after the bell was relatively muted on Thursday, with small-cap biotech names showing modest shifts. Delcath Systems edged higher following its buyback announcement, while BioVie, ...

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...

Nike recorded a lower profit and said it expects revenue to a decline in its current quarter. The stock fell 11% to $58.62 in after-hours trading Thursday. Cassava Sciences said the FDA had placed a ...

Stream Connecticut News for free, 24/7, wherever you are. Root: "Roots is a really great restaurant in Summit, New Jersey. Root, the one that you're referring to, is a not-so-great insurance ...

Cassava Sciences has rebranded as Filana Therapeutics, shedding the baggage associated with the old name as the biotech plants itself in a new therapeutic area. | Cassava Sciences has rebranded as ...